Leukocyte activation and cytokine production during experimental human endotoxemia

European Journal of Internal Medicine

Volumn 11, Issue 2, 2000, Pages 89-95

  Fijen, J W ^a   Kobold, A C Muller ^a,b   De Boer, P ^c,d   Jones, C R ^d   Van Der Werf, T S ^a   Tervaert, J W Cohen ^b   Zijlstra, J G ^a   Tulleken, J E ^a  

^a Department of Internal Medicine Div Rheumatology Stt Univ H   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c PRA International USA   (Netherlands)

^d RW Johnson Pharmaceutical Res I   (Switzerland)

Author keywords

Anti inflammatory response; Cytokine; Endotoxin; Leukocyte activation; Pro inflammatory response; Sepsis

Indexed keywords

CYTOKINE; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTOXEMIA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLAMMATION; LEUKOCYTE ACTIVATION; MALE; NORMAL HUMAN; SEPSIS; VOLUNTEER;

EID: 0034078662     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(00)00068-6     Document Type: Article

References (25)

1. Pajkrt D., Manten A., van der Poll T., Tiel van B., Jansen J., ten Cate J.W., et al. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood. 90:(4):1997;1415-1424.
2. van der Poll T., de Waal Malefyt R., Coyle S.M., Lowry S.F. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis. 175:(l):1997;118-122.
3. Zimmer S., Pollard V., Marshall G.D., Garofalo R.P., Traber D., Prough D., et al. The 1996 Moyer Award. Effects of endotoxin on the Thl/Th2 response in humans. J Burn Care Rehabil. 17:(6 Pt 1):1996;491-496.
4. van der Poll T., Coyle S.M., Barbosa K., Braxton C.C., Lowry S.F. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest. 97:(3):1996;713-719.
5. van Deventer S.J.H., Hart M., van der Poll T., Hack C.E., Aarden L.A. Endotoxin and tumor necrosis factor-alpha-induced interleukin-8 release in humans. J Infect Dis. 167:(2):1993;461-464.
6. Kuhns D.B., Alvord W.G., Gallin J.I. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis. 171:(1):1995;145-152.
7. Muller Kobold A.C., Tulleken J.E., Zijlstra J.G., Cohen Tervaert J.W. Interleukin-10 in febrile patients and patients with sepsis. Lancet. 351:1998;1587.
8. Muller Kobold A.C., Tulleken J.E., Zijlstra J.G., Cohen Tervaert J.W. Immunomonitoring in sepsis; correlations with disease state and mortality. Intensive Care Med. 23:(Abstract):1997;48.
9. Muller Kobold A.C., Kallenberg C.G.M., Cohen Tervaert J.W. Leukocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis. Br J Rheumatol. 37:(8):1998;901-907.
10. Muller Kobold A.C., Mesander G., Stegeman C.A., Kallenberg C.G.M., Cohen Tervaert J.W. Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides? Clin Exp Immunol. 114:(3):1998;491-499.
11. Muller Kobold A.C., Zijlstra J.G., Koene H.R., de Haas M., Kallenberg C.G.M., Cohen Tervaert J.W. Levels of soluble Fc gammaRIII correlate with disease severity in sepsis. Clin Exp Immunol. 114:(2):1998;220-227.
12. Fuchs D., Weiss G., Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol. 101:(1):1993;1-6.
13. Fuchs D., Weiss G., Reibnegger G., Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci. 29:(3-4):1992;307-341.
14. Muller Kobold A.C., Kallenberg C.G.M., Cohen Tervaert J.W. Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis. 58:1999;237-245.
15. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., et al. Detection of circulating tumor necrosis factor after endotoxin administration. New Engl J Med. 318:(23):1988;1481-1486.
16. van der Poll T., Lowry S.F. Epinephrine inhibits endotoxin-induced IL-1 beta production: roles of tumor necrosis factor-alpha and IL-10. Am J Physiol. 273:(6 Pt 2):1997;R1885-R1890.
17. Haveman J.W., Muller Kobold A.C., Cohen Tervaert J.W., Van den Berg A.P., Tulleken J.E., Kallenberg C.G.M., et al. The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth J Med. 55:1999;132-141.
18. Volk H.D., Thieme M., Heym S., Docke W.D., Ruppe U., Tausch W., et al. Alterations in function and phenotype of monocytes from patients with septic disease - predictive value and new therapeutic strategies. Behring Inst Mitt. 88:1991;208-215.
19. Docke W.D., Randow F., Syrbe U., Krausch D., Asadullah K., Reinke P., et al. Monocyte deactivation in septic patients: Restoration by IFN gamma treatment. Nature Med. 3:1997;678-681.
20. Bone R.C. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 24:(7):1996;1125-1128.
21. van Dissel J.T., van Langevelde P., Westerdorp R.G.J., Kwappenberg K., Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet. 351:1998;950-953.
22. Pinsky M.R. Balancing the inflammatory response in sepsis. Vincent J.L. Yearbook of intensive care and emergency medicine. 1998;3-13 Springer-Verlag, Berlin-Heidelberg-New York.
23. Bone R.C. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med. 125:(8):1996;680-687.
24. Bone R.C. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 24:(1):1996;163-172.
25. Vincent J.L. Search for effective immunomodulating strategies against sepsis. Lancet. 351:(9107):1998;922-923.